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1. Introduction 
Neurocysticercosis (NCC) is the most common disease causing cystic lesions in the central 
nervous system, especially in developing and tropical countries (1-5). Although 
neurocysticercosis is pleomorphic in its presentation, extraparenchymal neurocysticercosis 
may be challenging to diagnose and treat. With increasing globalization and international 
travel, NCC is now being reported from many developed countries such as the USA, UK 
and many European countries. Neurologists and neuroradiologists in these countries are 
often unaware of the pre-/post-treatment radiographic patterns of extraparenchymal NCC 
and the potentially poor prognosis if not correctly diagnosed and managed. Herein, we 
review the literature on extraparenchymal neurocysticercosis as a cause of meningitis and 
hydrochephalus and we discuss challenges in diagnosis and management of these cases.  
2. Definition  
Extraparenchymal neurocysticercosis (NCC) is defined as neurocysticercosis involving the 
subarachnoid, meningeal and intraventricular space (1;6;7). Thus, the clinical manifestations 
of extraparenchymal NCC range from asymptomatic lesions to meningitis and 
hydrocephalus (1;6;7). 
3. Epidemiology of extraparenchymal NCC 
Neurocysticercosis is the most common parasitic infestation of the central nervous system 
worldwide (1;4-7;11;12). Extraparenchymal NCC is frequently seen in Latin American 
countries whereas it is less common in the Indian subcontinent. Genetic differences in T. 
solium cysticerci have been reported from different countries (15) and may contribute 
towards the clinical variations across countries. These variations are perhaps due to complex 
interactions between the host, parasite and environmental factors (13;16-18). Cysticercal 
meningitis, although reported to constitute 42-48% of cases in Latin American case-series of 
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NC, is somewhat uncommon with <8% of cases having meningitis among adult patients (6-
9;19). Extraparenchymal NCC is also of emerging importance in developed countries (11;20). 
This increase likely includes extraparenchymal cases, and a recent study reported an overall 
frequency of subarachnoid cysts in 2%, ventricular cysts in 6%, and hydrocephalus in 16% of 
NCC cases (11). These cases represented almost one-third of NCC in a medical center in 
New Mexico (21). Intraventricular NCC, the presence of Taenia solium cysts in the cerebral 
ventricular system, occurs in 7–30% of patients with NCC (10;21-23).Thus, 
extraparenchymal NCC is probably more frequent than previously thought (14;18).  
4. Pathogenesis of extraparenchymal NCC 
4.1. Subarachnoid NCC 
The disease occurs when humans ingest eggs of Taenia solium from contaminated food (1). 
Brain parenchyma is most likely seeded through hematogenous dissemination and the 
ventricular system, subarachnoid space, and basal cisterns are then seeded via the choroid 
plexus (1). When cysts lodge outside the brain parenchyma (extraparenchymal NCC), they 
tend to grow irregularly depending on the space available and usually elicit a strong 
inflammatory response. Subarachnoid cysts can also grow abnormally as a membranous 
and/or cystic mass called racemose cysticercosis (7). Occasionally the cysts enlarge 
considerably, become racemose without scolices and cause mass effects. Cysticercus 
racemose is characterized by larger size (4–12 cm), absence of scolex and a variable 
appearance. Cysticercus racemosus is a form multilobular grape-like cluster without scolex 
thought to be a forme fruste of cysticercus cellulosae (24), most frequently located in the basal 
cisterns, Sylvian fissure, or ventricles (10;21-23).These cysts continually grow  compared 
with intraparenchymal NCC and commonly result in basilar arachnoiditis (7) with 
inflammation and fibrosis in and around critical structures, causing meningeal 
inflammation, hydrocephalus due to CSF outflow obstruction, or cerebrovascular 
complications (10;21-23). The cyst often tends to migrate to the fourth ventricle because of 
gravity and CSF flow patterns (10;21-23). Although neurocysticerci undergo four stages of 
involution: vesicular, colloidal, granulovacuvolar and calcific, this evolution does not occur 
in the intraventricular or the subarachnoid forms (or racemose type) of NCC (25). 
4.2. Cysticercal meningitis 
“Racemose” cysticercosis is associated with an intense inflammatory reaction and 
progressive thickening of the leptomeninges at the base of the brain. Signs of meningitis, 
cranial nerve palsy and cerebral infarcts secondary to vasculitis may also develop (26). In 
approximately 50–60% of the cases, there is an obstruction of the CSF circulation, resulting 
in progressive intracranial hypertension and hydrocephalus and mortality of over 20% of 
cases (26). When hydrocephalus secondary to cysticercotic meningitis is present, the 
mortality rate is high (50%) and most patients die within 2 years after CSF shunting(4). 
Therefore, basal cisternal locations are considered to be malignant forms of NCC (26). 
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4.3. Intraventricular NCC 
Hydrocephalus can result either because of direct obstruction of cerebrospinal fluid (CSF) 
pathways by intraventricular cysts or secondary to inflammatory obstruction. 
Intraventricular neurocysticercal cysts occur singly or in multiples and frequently coexist 
with parenchymal and sub-arachnoid cysts (10;21-23). Intracranial hypertension is a 
common manifestation of extraparenhymal NCC and the increased intracranial pressure can 
be from the mass effect of a giant subarachnoid cyst (27), or from obstructive hydrocephalus 
produced by direct obstruction of the ventricular system by a cyst (28), distortion of 
ventricular CSF pathways (29), or blockage of CSF pathways within the subarachnoid space 
from the inflammatory reaction (28). However, a cyst in the fourth ventricle tends to be 
solitary, without accompanying parenchymal cysts (10;21-23). 
4.4. Extramedullary cysticercosis 
Involvement of the spinal cord is rare, accounting for 1–5% of all cases of NCC (30;31). 
Spinal NCC may be intramedullary or extramedullary (intradural or extradural); however 
these forms are rare, and most disease involves the subarachnoid spaces, which may result 
from direct CSF dissemination (30;31). It has  been suggested that small, or developing 
larvae present in the subarachnoid space settle to the basal cisterns by way of gravity and 
then further descend into the subarachnoid spaces of the lower parts of the spine including 
the lumbosacral space where they find adequate room to grow and develop (30;31). Many of 
the pathologic descriptions of cysticerci recovered from the spinal canal have a racemose 
morphology, which consists of membranous cells that proliferate, which may cause seeding 
of the spine from the base of the brain and subsequent growth (30;31). Cervical involvement 
consists mostly of unilocular or multilocular cystic forms, primarily due to direct extension 
of cysts located in the basal subarachnoid cisterns (30;31). Conversely, lumbosacral 
involvement has a more varied picture including multilocular cystic lesions causing spinal 
displacement or flattening, and clumping or displacement of the nerve roots most likely due 
to adhesive arachnoiditis (30;31). Clinical signs can be caused by direct compression of the 
spinal cord and/or roots by cysticerci or, indirectly, by the inflammatory reaction, including 
progressive paraparesis and sphincter disturbances.  
4.5. Orbital neurocysticercosis 
Ocular cysticercosis is caused by the growth of the larvae of Taenia solium within the ocular 
tissues and the cysts may be located in descending order of frequency, subretinal space 
(35%), vitreous (22%), conjunctiva (22%), anterior segment (5%) and orbit (1%)(32). The 
extraocular muscle form is the most common type of orbital cysticercosis (33-35). In the 
ocular form, the most favored sites are the vitreous and the subretinal space whereas the 
inferior rectus and the medial rectus are the most common extraocular muscles involved 
(33-35). Intraocular cysticercosis is predominant in the Western countries, whereas 
extraocular is more common in the Indian population and several authors have attributed 
geographic and environmental factors to this difference (33-35). The continuation of the 
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retina with the optic nerve allows direct communication of the subarachnoid space with 
subretinal space but it remains unclear whether subretinal NCC can be considered another 
form of subarachnoid NCC (33-35).  
There is lack of understanding of the pathophysiology of extraparenchymal NCC. 
Circulating antigen detection assays could help establish if living parasites are still present 
after apparent radiographic cyst regression, providing an indication to continue or reuse 
antiparasitic treatment (36). It is unclear whether chronic inflammation in extraparenchymal 
NCC is due to continuous cyst degeneration, or continuous antigen release from dead 
parasitic tissues (37). Newer mechanisms are being explored to understand the complex 
neuropathology and heterogeneity of NCC. 
5. Clinical manifestations of extraparenchymal NCC 
The clinical and radiologic manifestations of NCC are pleomorphic. Epilepsy, present in 
both intraparenchymal and extraparenchymal NCC, focal neurological signs, and headache 
are the most common clinical manifestations of the disease (1;38). Focal neurological signs 
that vary according to the size, number and location of the parasites have been described in 
up to 20% patients with neurocysticercosis (1;38). Pyramidal tract signs predominate, but 
sensory deficits, involuntary movements, and signs of brainstem dysfunction, may occur in 
some patients (1;38). These manifestations usually follow a subacute or chronic course 
resembling that of a brain tumor and are most often seen in patients with large 
subarachnoid cysts compressing the brain parenchyma (1;38). Thus,  several varieties of 
NCC have been recognized depending upon the number, location, and evolutionary stage of 
the cysticerci in the human brain (39). 
Extraparenchymal NCC occurs mainly in young adult males and is uncommon in children 
(38;40). The patients typically present with subacute or chronic intracranial hypertension 
from mass effect or hydrocephalus; chronic meningitis characterized by lack of meningeal 
signs of exam, often due to chronicity of symptoms , a mild-to-moderate CSF lymphocytic 
pleocytosis and moderate-high increase in protein; radiographic hydrocephalus with or 
without obvious cysts; radiographic presence of cysts in the ventricles or subarachnoid 
space and protracted clinical or radiographic course after antiparasitic treatment (8;21). 
Stroke can occur secondary to vasculitis caused by inflammatory occlusion of the arteries at 
the base of the brain secondary to arachnoiditis (4;5;12). 
Hydrocephalus develops in approximately 30% of all patients with NCC because of 
obstruction by intraventricular or subarachnoid lesions (10;21-23). Intraventricular NCC 
can cause non-communicating hydrocephalus by obstructing the CSF pathway and 
communicating hydrocephalus by development of ependymitis (10;21-23). Abrupt 
permanent obstruction can cause sudden death due to brain herniation (10;21-23). Life-
threatening acute intermittent hydrocephalus (Brunn syndrome)(41) can occur due to 
cyst-inducing intermittent CSF obstruction from a ball-valve mechanism  (10;22). Overall, 
extraparenchymal NCC has a more aggressive behavior and a higher morbidity and 
mortality rate than parenchymal form (10;21-23). Presence of sub-arachnoid cysts can 
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cause chronic cysticercal meningitis. Cysticercal meningitis (CM) is characterized by 
inflammatory cerebrospinal fluid (CSF) and negative bacterial and fungal cultures (8). 
There have been no systematic studies of CM. In a recent study of patients with CM these 
patients often had intracranial hypertension, meningeal signs, CSF hypoglycorrachia, 
positive CSF results in an enzyme-linked immunosorbent assay (ELISA) for cysticercal 
antigens, negative CSF cultures for bacteria, fungi, and mycobacteria and longer clinical 
course of NCC (8). The management of the chronic inflammation and the complications 
caused by this meningitis are usually very difficult, and the mortality rate can be up to 
33% (10;21-23). It is likely that CM is often not identified and its correct identification may 
reduce morbidity and risks of unnecessary surgery in patients with chronic 
neurocysticercosis and CSF shunts (10;21-23). 
6. Diagnosis of extraparenchymal NCC 
The diagnosis of NCC is often made based on presence of  lesion highly suggestive of 
neurocysticercosis on neuroimaging study , positive serum immunoassay for the detection 
of anticysticercal antibodies , positive CSF immunoassay for detection of anticysticercal 
antibodies and epidemiologic criteria including individual coming from an area where 
cysticercosis is endemic (1).These diagnostic criteria have been  stratified in four 
categories—absolute, major, minor, and epidemiological- on the basis of their individual 
diagnostic strength(1). Based on a previous consensus, the absolute criterion for the 
diagnosis of neurocysticercosis that is being considered as pathognomonic of this disease is 
the detection of a scolex inside a cyst by CT or MRI  although, C. racemosus doesn't have a 
scolex (1). 
6.1. Clinical presentation 
Extraparenchymal NCC is associated with a local inflammatory response with high 
protein concentration and cell counts in the CSF (8). Clinical manifestations and CSF 
findings are similar to the more common tuberculous meningitis, (8;23) and other forms of 
chronic meningitis including  chronic HIV- associated meningitis (42;43) since the CSF 
findings consist of pleocytosis (usually lymphocytic but frequently polymorphonuclear) , 
reduced glucose and elevated protein(8). In one series of cysticercal meningoencephalitis, 
confusion with tubercular meningitis was present in 61.5% cases (7;8). An important 
differentiating feature with these other forms of chronic meningitis is the presence of 
eosinophils in the CSF (7;8) which is usually seen only in the initial phases of the illness 
(8;21). However, this staining of the CSF is not routinely done in most places (8;23). 
Although the suspicion of NCC as the cause of chronic meningitis is increased when CSF 
eosinophils are found, CSF eosinophils (above 5%) occur in only 15% of patients (21). It is 
often a common practice to attribute chronic meningitis and hydrocephalus to tubercular 
meningitis in the presence of appropriate epidemiologic history and treat empirically by 
shunting and anti-tubercular  therapy. Thus, an astute clinical acumen is required to make 
the diagnosis of CM. 
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6.2. Imaging  
Both computed tomography (CT) and magnetic resonance imaging (MRI) are indispensable 
tools for diagnosis and characterization of NCC (38;44;45); CT is superior for diagnosis of 
racemose cysticercosis, brain granulomas and calcifications, which are the most frequent 
finding of NCC, and may be missed by MRI (38;44;45). However, neuroimaging findings of 
extraparenchymal cysticerci are subtle and are usually not seen by CT. Thus, MRI is more 
useful than CT for diagnosis of ocular, ventricular, and subarachnoid cysticercosis and for 
analysis of the inflammatory reaction that accompanies most cases of active NCC (38;44;45).  
Neuroimaging findings are variable depending on the stage of the infection. The first stage, 
described as the larval tissue invasion phase, is not normally imaged owing to lack of 
symptoms at this very early stage (1;46). During the vesicular stage, cysts and scolex, the 
"mouth" of the tapeworm that is lined with suckers and hooks, are both imaged without 
enhancement. However, as observed in one study(47) in which imaging was performed 
regularly to follow anticysticercal therapy, this phase appears as a localized focus of edema 
on T2-weighted images and displays nodular tissue enhancement following the 
administration of gadopentetate dimeglumine (1;46). 
The second stage (the vesicular stage) describes the formation of a cyst that encircles the 
scolex (1;46). These cysts are thin walled, contain clear fluid and are typically 1-2 cm. On 
imaging, the cyst fluid parallels cerebrospinal fluid intensity. The scolex is approximately 2–
4 mm and appears as a mural nodule that is isointense with brain parenchyma (48). The 
lesion is antigenically inert and therefore does not induce an inflammatory reaction or 
circumferential edema (49).  
During the third stage (the colloidal stage) the parasite dies, and as a result the cysticercus 
becomes nonviable (1;46). As the scolex dies, the cyst fluid transforms into a colloidal 
suspension containing protein solutes (1;46) and on MRI imaging this results in T1 
shortening while the scolex and cyst capsule are decreased in T2 signal intensity. The 
surrounding edema suggests that the parasite is in its colloidal state, and, therefore, 
enhancement of the capsule and scolex will occur avidly. In addition, the proteinaceous 
nature of the cyst fluid during involution of the cysticercus is  appears as hypointense 
central T1 signal to white matter but hyperintense to cerebrospinal fluid and appears 
markedly hyperintense on T2-weighted images (1;46). At CT, cystic contents increase in 
attenuation (50). Thus, in the colloidal vesicular stage, ring enhancement and edema are 
appreciated by both CT and MRI imagings (1;46). 
The fourth stage (the nodular granular stage) represents the degeneration of the cysticercus. 
The edema begins to subside gradually, the contents begin to mineralize and the cyst 
involutes. Thus, the lesion becomes isointense with brain parenchyma on T1-weighted MR 
images and hypointense on T2-weighted MR images. At CT, a thick nodular ring continues 
to enhance and the lesion becomes isoattenuating (51).  
The final stage is the calcified stage, which describes complete involution of the lesion with 
continued mineralization. The calcifications are obvious at CT as small areas of 
 
Extraparenchymal Neurocysticercosis 355 
hypointensity (1) and show susceptibility at MR imaging, particularly on gradient-echo 
images (47). However MRI is not the imaging modality of choice for calcified NCC (47). 
Also, in the nodular calcified stage, when the cystic lesion is mineralized and shrunken and 
a nonenhanced CT scan is diagnostic, enhancement is unusual (51). The granular nodular 
phase is characterized by decreased ring enhancement and edema, along with the 
calcification of cysts (46).  
Subarachnoid (racemose) neurocysticercosis usually infiltrates the basal cisterns and sylvian 
fissure and has different imaging findings compared to parenchymal NCC. Common 
neuroimaging findings to suspect the diagnosis include hydrocephalus (with or without 
obvious cysts), cysts obstructing CSF pathways or freely floating inside ventricles, cysts in 
the basal subarachnoid cisterns, migrating cysts across the cerebral aqueduct, and 
ependymitis or arachnoiditis (21). The most common CT finding in subarachnoid NCC is 
hydrocephalus (1;9). Because the cyst membrane is thin and the fluid is isodense with the 
cerebrospinal fluid, uninflamed extraparenchymal cysticerci are usually not visible on 
computed tomography scanning and may only reveal subtle, indirect findings on MRI (9). 
Therefore, neuroimaging may reveal hydrocephalus without noticeable cysts (1;9). 
6.3. Laboratory tests for diagnosis of NCC 
Taenia antibodies detected by methods such as Western Blot is considered as a major 
criterion whereas the positive serologic test in the CSF is listed as a minor criterion (19).The 
development of numerous serodiagnostic tests using different parasitic antigens is 
indicative of the fact that none of them are 100% sensitive and specific. For multiple lesions, 
the enzyme-linked immunoelectrotransfer blot (EITB) assay using purified glycoprotein 
antigens from T. solium cysticerci was reported to be highly specific (100%) and nearly 98% 
sensitive (4;5;12). The sensitivity was less for single lesions (52)and for calcified lesions 
(2;2;53-56). A comparative study of enzyme-linked immunosorbent assay (ELISA) and dot-
blot assay in children found that both were more sensitive in cases with multiple brain 
lesions (100%) than in those with a single lesion (87%) (5). The sensitivity of antibody 
detecting EITB assays is not better with the use of CSF samples as compared with serum 
samples (55). Detection of circulating cysticercosis antigens using ELISA has a modest 
sensitivity especially for parenchymal lesions. The antigen detecting ELISA has a better 
sensitivity with the use of CSF samples as compared with serum samples. However, ELISA 
has less sensitivity as compared with EITB for serum as well as CSF samples, for both 
intraparenchymal and extraparenchymal NCC (55;57-59).  
It has been suggested that the use of excretory secretory (ES) antigens, rather than somatic 
antigens might improve the serodiagnosis of cases with vesicular stages of the parasite 
(60;61). The use of ES antigens for the detection of antibodies in serum was found to be more 
useful than that in urine in patients with enhancing lesions (62). Three ES peptides were 
reported to have high sensitivity and specificity in both serum and CSF reactivity; (60;61). It 
has been suggested that synthetic peptide selected by phage display may be useful in the 
immunodiagnosis of NCC (63;64). 
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Polymerase chain reaction (PCR) in CSF has also been used for the diagnosis of 
neurocysticercosis but is not widely available (19). However, extensive and comprehensive 
revision of the diagnostic criteria of neurocysticercosis, especially of extraparenchymal 
neurocysticercosis is mandatory according to many recent publications (2;8-11). 
7. Treatment 
There is still no consensus regarding optimal treatment strategies in patients with 
extraparenchymal NCC (10;21-23). Various therapeutic modalities include antihelminthic 
medication, microneurosurgical removal, ventriculoperitoneal shunting, and endoscopic 
management (8). 
7.1. Medical therapy 
Although parenchymal cysts have historically been treated quite effectively with 
antihelminthics such as praziquantel and albendazole, medical therapy alone is not favored 
for extraparenchymal NCC because of the limited efficacy in such cases, and a risk of 
developing acute hydrocephalus during the clinical treatment period (10;21-23). Good 
results for antiparasitic treatment with different albendazole and praziquantel regiments for 
extraparenchymal NCC including orbital, spinal , intraventricular and subarachnoid NCC, 
and even for giant cysts have been reported (57;65-69) although resistance has been reported 
by some (13;16;17). However, although treatment with antihelminthic medication such as 
albendazole has been shown to improve outcome in live, cystic parenchymal cysticercosis, 
the benefits of antihelminthic treatment in patients with solitary cystic lesion remain 
uncertain (70). While it is generally accepted that both praziquantel and albendazole are 
effective in destroying viable cysts, their use in cases with enhancing lesions has been 
debated as these lesions are considered to represent degenerating cysts, many of which 
resolve spontaneously (4;5;12). Thus, the decision whether antiparasitic treatment should be 
used in these cases is always a clinical decision and should be made on an individual basis.  
Antihelminthic agents hasten the evolution of intraventricular viable cysts, which may 
trigger an inflammatory response similar to that seen with the natural history of the parasite 
(25). This may result in long-term sequelae (1;6;9;71). Extraparenchymal cysts may regress 
only after long term and multiple antiparasitic courses (1;6;9;71). The optimal treatment to 
prevent chronic inflammation is unknown due the lack of understanding of its 
pathophysiology and lack of controlled trials to help guide management. Likewise, 
controversy exists regarding the use of corticosteroids, alone or in combination with 
antihelminthic drugs (1;6;70;71). At a previous consensus meeting, experts agreed that no 
single treatment approach could be advocated and that management options varied 
according to the type of clinical presentation (9). However, intraventricular 
neurocysticercosis has a risk of ependymitis in those treated with anthelminthics such as 
albendazole and praziquantel regiments. Thus these agents should be used with caution in 
cases with extraparenchymal NCC as any increase in the inflammatory response may lead 
to the development of infarct; pretreatment with steroids and management of intracranial 
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hypertension is warranted  and surgical evaluation is often needed prior to medical 
treatment (8).  
7.2. Surgical therapy 
In patients presenting with acute hydrocephalus, surgery is the only option (10;21-23). 
Neurosurgical procedures for NCC are still part of the armamentarium when treating this 
disease and good results for open craniotomy and rigid endoscopic surgery in patients with 
intraventricular and subarachnoid NCC have been reported (72;73). Infratentorial 
intraventricular cysts have been treated with open surgery for excision whereas it is 
generally suggested that supratentorial cysts, due to not only location but also the need to 
often treat hydrocephalus in these patients, be removed endoscopically (74). Ependymitis, 
confirmed by neuroimaging is a relative contraindication for surgical removal of the cysts 
(10;21-23).  
Ventriculoperitoneal CSF shunting is burdened by a high shunt dysfunction rate which 
leads to worsening obstruction of CSF flow and increased intracranial pressure, risk of 
infection and thus high mortality rates. Microneurosurgical approaches can be technically 
demanding and associated with various complications (10;21-23). For these reasons, 
endoscopic approaches for intraventricular neurocysticercosis have been described in recent 
years and often allow for cyst removal and hydrocephalus treatment, freeing the patient 
from shunt procedures (75;76). 
Although the literature regarding the use of endoscopic management of intraventricular 
NCC is scarce, this modality has shown encouraging results in the treatment of 
intraventricular NCC (10;21-23). In a recent comparative study of 140 patients from Mexico 
with intraventricular NCC, traditional treatment with albendazole and steroid had similar 
outcome versus neuroendoscopic surgery in terms of survival, hospitalization (23). 
However, almost all patients with traditional treatment remained with at least one shunt 
whereas most of the patients from the neuroendoscopic surgery series did not have any 
shunts (23). Thus, the neuroendoscopic approach to intraventricular neurocysticercal cysts is 
safe and effective and offers the additional benefit of avoiding shunt placement (10;21-23). 
At centres having the required expertise, this should be the treatment of choice. Traditional 
treatment is a second option where the endoscopic procedure is not available. However, 
endoscopic cyst excision can be difficult and hazardous in patients with severe ependymitis 
and dense adhesions and intraventricular bleeding could also report (10;21-23). Thus, 
despite its many advantages, neuroendoscopy has some limitations even when performed 
by experienced hands. 
Regarding subarachnoid NCC, there are no controlled trials on the management of this form 
of extraparenchymal NCC (1;6;71). In a series of patients treated with only CSF diversion, 
50% died at a median follow-up of 8 years and 11 months (2). More recently, case series 
using anti-parasitic drugs, corticosteroids, and shunting for hydrocephalus have been 
associated with an improved prognosis compared with older studies (1;2;6;71).Thus, most 
experts consider subarachnoid NCC a clear indication for anti-parasitic therapy (2). 
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However, the optimal dose and duration of anti-parasitic therapy for subarachnoid 
cysticercosis has not been established (2). In the largest cases series, Proaño and others 
treated 33 patients with giant cysticerci with albendazole (15 mg/kg/day) for 4 weeks and 
most patients required several courses of anti-parasitic therapy (23). However, with 
controversy in the literature in the optimal management of this condition and without 
further evidence-based guidelines to help management of extraparenchymal NCC, the 
decision of the total dose and duration of antiparasitic and steroid therapy must be made on 
a case by case basis.  
8. Conclusion 
Extraparenchymal NCC may be a more common form of NCC than previously thought and 
is often difficult to diagnose, more complex to treat, and carries a graver prognosis. The 
clinical course is protracted and difficult to cure. Different medical (anthelmintics, steroids), 
surgical (cyst excision, CSF diversion), or medical-surgical approaches have been reported 
but not adequately studied. Because clinicians in developed countries often unfamiliar with 
NCC as a cause of chronic meningitis, chronic ventriculitis, or hydrocephalus without 
obvious cysts, the diagnosis of extraparenchymal NCC often depends on the correct 
interpretation of neuroimaging which may miss the diagnosis. Thus, extraparenchymal 
NCC should always be considered by clinicians and radiologists in the differential diagnosis 
of chronic meningitis and hydrocephalus.  
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